iCAD (NASDAQ:ICAD) Shares Pass Above Two Hundred Day Moving Average of $1.51

iCAD, Inc. (NASDAQ:ICAD) shares passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $1.51 and traded as high as $1.61. iCAD shares last traded at $1.56, with a volume of 72,286 shares trading hands.

Wall Street Analysts Forecast Growth

Separately, StockNews.com raised shares of iCAD from a “sell” rating to a “hold” rating in a research report on Thursday, August 22nd.

iCAD Price Performance

The company has a fifty day moving average of $1.37 and a two-hundred day moving average of $1.51. The stock has a market capitalization of $42.73 million, a P/E ratio of -13.42 and a beta of 1.50.

Institutional Investors Weigh In On iCAD

Institutional investors have recently modified their holdings of the business. Salem Investment Counselors Inc. bought a new position in iCAD during the 1st quarter worth $119,000. First Eagle Investment Management LLC increased its holdings in shares of iCAD by 2.8% in the 4th quarter. First Eagle Investment Management LLC now owns 679,525 shares of the technology company’s stock worth $1,203,000 after acquiring an additional 18,689 shares during the period. AMH Equity Ltd bought a new stake in iCAD in the 1st quarter valued at about $207,000. Perritt Capital Management Inc lifted its position in iCAD by 14.2% in the 2nd quarter. Perritt Capital Management Inc now owns 159,900 shares of the technology company’s stock valued at $208,000 after purchasing an additional 19,917 shares during the last quarter. Finally, Virtu Financial LLC boosted its stake in iCAD by 55.6% during the 1st quarter. Virtu Financial LLC now owns 21,286 shares of the technology company’s stock valued at $34,000 after purchasing an additional 7,604 shares during the period. Institutional investors own 24.61% of the company’s stock.

About iCAD

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.